Short Interest in Fidelity Disruptive Medicine ETF (NASDAQ:FMED) Expands By 125.0%

On March 16th, 2025, a significant rise in short interest for the Fidelity Disruptive Medicine ETF (NASDAQ:FMED) was reported. As of February 28, 2025, the short interest had surged to 900 shares, marking a remarkable increase of 125.0% from the 400 shares recorded on February 13, 2025. This figure indicates that approximately 0.0% of the ETF's total shares are currently sold short. Given an average daily trading volume of 5,700 shares, the short interest ratio stands at a mere 0.2 days, suggesting that short trading is relatively low in comparison to the total shares held.

Institutional Trading of Fidelity Disruptive Medicine ETF

In recent institutional trading developments, Jane Street Group LLC has considerably amplified its stake in the Fidelity Disruptive Medicine ETF. According to the latest 13F filing with the Securities and Exchange Commission, the firm raised its position by 200.4% during the third quarter. After this increase, Jane Street Group LLC now holds 61,342 shares of FMED stock, which includes an additional 40,924 shares purchased during the reporting period. This stake accounts for approximately 2.92% of the Fidelity Disruptive Medicine ETF, valued at roughly $1,613,000 as of the latest reporting.

Fidelity Disruptive Medicine ETF Stock Performance

On the trading floor, FMED opened at a price of $24.03 on a recent Friday. The ETF has experienced fluctuation within the past year, with a 12-month low of $23.32 and a high of $26.79. The stock's performance can be further assessed with a fifty-day simple moving average of $25.50, while the 200-day simple moving average is noted at $25.70. With a total market capitalization of $50.46 million, the ETF has a P/E ratio of 42.34 and a beta value of 0.94.

Dividend Announcement from Fidelity Disruptive Medicine ETF

In addition to the changes in trading activity, the Fidelity Disruptive Medicine ETF has announced an increase in its quarterly dividend. This announcement came in conjunction with its recent payout on December 24th, 2024. Shareholders who were on record as of December 20th received a dividend payment of $0.112 per share. The ex-dividend date was also set on December 20th. This marks a significant rise from the previous quarterly dividend of $0.00, now reflecting an annualized dividend total of $0.45, yielding 1.86%.

Fidelity Disruptive Medicine ETF Overview

The Fidelity Disruptive Medicine ETF (FMED) stands as an actively managed exchange-traded fund focusing primarily on health care equities. It is designed to invest in companies that are spearheading innovative changes in the healthcare sector. Since its inception on April 16, 2020, the fund continues to evolve under Fidelity's management, maintaining a strategic focus on both domestic and international issuers.

short, interest, ETF